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Purpose: To review the current status of hypoxia PET 
imaging for delineating hypoxic volumes (HVs) inside the 
gross target volume (GTV) and for radiotherapy (RT) outcome 
prediction. 
Methods: Hypoxia PET tracers currently used in clinical trials 
are mainly [18F]-FMISO, [18F]-FAZA and [18F]-HX4. Different 
image acquisition protocols and methods for delineating HVs 
will be presented in this talk. Furthermore, results of recent 
clinical trials will be reviewed where the prognostic value of 
hypoxia PET imaging before and during RT with respect to 
outcome as investigated. 
In our institution, a clinical phase II trial is currently carried 
out where to date n=33 head and neck cancer patients were 
included. Patients were examined using dynamic FMISO PET 
imaging plus conventional FDG PET imaging in addition to 
planning CT and eventually MRI before the start of RT. HVs 
were segmented based on parameters derived from the 
pharmaco-kinetic analysis of the dynamic FMISO PET data. 
Patients were randomized into two treatment arms. Patients 
in the experimental arm were treated with a 10% dose 
escalation to the HV whereas patients in the control arm 
received standard IMRT treatment with 70 Gy in 35 fractions.  
Results: Different manual and (semi-)automatic methods for 
HV delineation based on hypoxia PET data have been used in 
clinical studies, such as thresholding, tumour-to-background 
ratio (TBR) based methods, advanced automatic methods or 
delineations based on dynamic PET imaging. Different 
contouring techniques for HV definition may result in strongly 
varying volumes. Recently published clinical trials confirm 
the prognostic character of hypoxia PET imaging. However, 
no consensus was found yet with regard to the timing of the 
hypoxia PET examination. Some studies found that pre-
treatment hypoxia PET information was correlated to 
outcome whereas others stated that hypoxia PET data 
acquired two weeks into RT had prognostic value. 
For our hypoxia dose painting trial, a planned interim analysis 
was carried out after recruiting n=20 patients. Median follow-
up time for this group was 36 (11 - 52) months. 5 patients did 
not show any tumour hypoxia (HV = 0 mL). The mean HV of 
the hypoxic tumours was 8.6 mL (0.3 – 49.2 mL). 
Furthermore, data acquired in this study could confirm a 
prognostic model relating TCP to a measure derived from 
dynamic FMISO PET imaging acquired before the start of RT. 
Conclusion: Hypoxia PET imaging is a very promising tool for 
the stratification of patients into different risk groups and 
thus a potentially very interesting molecular marker in the 
advent of biologically adapted, personalized RT. However, a 
comparison of results from different clinical trials is difficult 
due to large discrepancies in terms of imaging protocols and 
data analysis strategies. 
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Pre-RT MR spectroscopic imaging ( MRSI) has been described 
as a promising non invasive tool to depict GBM behaviour and 
extension. 
We confirmed this based on data from an in-house 
prospective clinical trial for GBM, analysing both pre and 
relapse MRSI and published the predctive value of Cho/NAA>2 
( CNR2) regions for the site of relapse .  We then elaborated 
a dose-painting clinical trial aiming to increase dose to CNR2 
regions on biopsied or resected glioblastoma. 
First, as MR spectroscopy metabolic maps are not delivered in 
a DICOM format, we developed an automated image 
processing tool for MR  spectroscopy data integration onto 
planning CT. 
Then we performed a dosimetric study for each patient, 
comparing doses to organs at risk with three different 
treatments : 1) with conventional 3D RT at 60 Gy / 2 Gy 
fractions targeted to contrast enhancement, CE + 2cm ) same 
treatment with an addition SIB IMRT, Simultaneous Integrated 
Boost with Intensity Modulated RadioTherapy ( i.e. 2.4 Gy by 
fraction on the boost), the boost being the MR spectroscopy 
abnormalities ( Cho/NAA ratio>2 + 1cm)  3) SIB IMRT targeted 
to MR Spectroscopy abnormalities + contrast enhancement + 
3mm . Then the V10 Gy and V40 Gy to normal brain and V54 
to brainstem were compared. The dosimetric comparaison 
showed that the doses to organs at risk were lower with 
increased dose SIB IMRT 72 Gy than with standard 60 Gy 
conventional RT and equivalent to 60 Gy IMRT.  The size of 
the SIB could be increased to spectral abnormalities + 
contrast enhancement without increasing dose to organs at 
risk. 
Finally,  we started in 2011 a prospective  phase III 
randomized clinical trial SPECTRO GLIO, financed by the 
French national Cancer Institute ( INCa). The goal is the 
inclusion of 220 patients treated in 9 french centers.  
Standard treatment delivers 60 GY+ Temozolomide, targeted 
to CE+2cm;  patients included in the experimental arm 
receive an additional 72Gy SIB targeted to MRSI 
abnormalities+1cm and to Contrast enhancement. The 
endpoint is survival. 
This ongoing trial includes a centralized MR spectroscopy 
post-treatment  and CHO/NAA>2 maps integration to planning 
CT . Target volumes and Organs at risk delineation are also 
centralized at our institution for all participating centers.  
An external online quality control of the dosimetry is 
performed for each patient included in the experimental 
arm. 
Patients undergo MRI and MRSI before and every two months 
after RT, as well as MR perfusion and diffusion.  
We  recently published a preliminary study of Lactate on 
MRSI, as lactate is a surrogate of tumor hypoxia and 
radioresistance.  We defined a lactate/NAA>0.4  threshold , 
having a  predictive value for the site of relapse. This data 
will have to be confirmed on the larger set of data from the 
Spectro GLio trial as well as MR diffusion and perfusion that 
are performed longitudinally in this trial.  
Conclusion: In our talk we will describe the different steps of 
a dose-painting clinical trial based on metabolic imaging with 
MRSI in GBM: 
-        study of  the predictive value for the site of relapse of 
GBM  
-        developping a quantification and integration method of 
the metabolic maps into planning CT 
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-        performing a preparatory dosimetric study to use a 
dose-escalation 
-        runnning a multicentric phase III randomized dose-
painting prospective clinical trial, Spectro Glio, with 
centralized contouring and online quality control of the 
dosimetry for the experimental arm 
-      preparing methods for analysis of multimodal imaging 
gathered during this trial in order to further improve the 
definition of the optimal Biological Target Volume. 
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Introduction: In literature the term « dose reconstruction” 
has been used for several concepts. In radioprotection it is 
defined as the accumulation of radiation doses received by 
workers or patients (radiology e.g.). In this presentation the 
focus is on radiotherapy applications and more concretely on 
the measure of the actually delivered dose, received by the 
patient during a dynamic treatment. As treatments are 
becoming more and more complex, using flattening filter free 
beams, high dose rates, dose escalation, hypofractionation, 
and gating or tracking strategies, while irradiating moving 
geometries, one can expect that the actually delivered dose 
will deviate from the planned one. Delivery QAs in a 
homogeneous phantom using in plane gamma analysis do not 
seem adequate. 
Overview delivery QA methods: Setup-
uncertainties/robustness: Can be evaluated by convolving the 
PDF of the tumor position with the dose. Convolving this PDF 
with the 2-D fluence of each individual beam corrects for the 
shift invariance assumption. An alternative method is 
modifying the isocenter position of each individual beam in 
the RTPlan file for dose reconstruction. 
Static delivery QA of a single fraction: In EPID dosimetry the 
exit fluence measured by the portal imaging device is 
reconstructed to dose in the patient. On a Tomotherapy 
machine, the MVCT data obtained during the treatment can 
be used for this purpose. The method of Feygelman et al uses 
a phantom measurement-based perturbation map to include 
the impact of dynamic delivery in the TPS dose. This method 
can also be used to estimate the impact of patient motion. 
Machine log files can be used and dose calculation can be 
performed on cone beam CT or MVCT. 
4D Intra-fraction dose accumulation: The dose corresponding 
to the original RTPlan is calculated on the different CT 
phases of the 4D CT. Deformable registration between the 
phases allows warping the dose to the reference scan for 
dose accumulation. This does not consider the interplay 
effect. A more precise approach is to use the machine log 
files allowing synchronization of the individual CPs with the 
breathing phase. Phase specific RTPlan files are generated to 
calculate the phase specific dose. An alternative is the 
uniform time sampling technique introduced by Litzenberg et 
al. using a dedicated MC dose calculation engine. Even more 
precise would be to calculate dose on a 4D cone beam CT.  
Inter-fraction dose accumulation: For each individual fraction 
the log files are used to calculate the delivered dose on the 
cone beam CT or MVCT images. All fraction scans are 
deformed to the planning CT for dose warping. The use of 
congruent energy/mass warping is preferable for this 
application as the geometry change can be more important. 
There remain unanswered questions though: what is the 
impact of voxels being lost (weight loss, tumor shrinkage, 
OAR shrinkage, …). The quantity “dose” might not be optimal 
for accumulation in shrinking organs.  
Conclusion: The dose reconstruction methods are rapidly 
evolving. Different levels of approximation and accuracy are 
possible. A further evolution in in-room imaging such as 4D 
cone beam CT might increase precision and provide the 
actually delivered dose. This will even be more relevant in 
proton therapy. The knowledge of the delivered dose might 
lead to a better understanding of biological effects related to 
the treatment and to more robust planning strategies. The 
accumulation of inter-fraction dose remains a challenge 
where the physical concept of dose probably needs to be 
replaced by organ specific parameters that can be 
accumulated, such as the absolute volume of a parallel organ 
(e.g. the parotids) that receives a dose below a certain 
threshold. 
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Introduction:Stereotactic body radiation therapy is a rapidly 
expanding technique, requiring high delivery accuracy 
because of the applied hypofractionation with high fraction 
and total doses. At conventional linacs, doses can be 
delivered with coplanar and non-coplanar beam 
arrangements, while dedicated machines like the Cyberknife 
and the Vero have their own unique treatment approaches. 
Performing unbiased plan comparisons may be time 
consuming and difficult due to user dependency and the trial-
and-error procedure needed in manual planning. In our 
institute, a home-made optimizer, Erasmus-iCycle (Breedveld 
et al., Med Phys. 2012; 39(2): 951), has been developed for 
fully automated plan generation. Due to the automation, this 
optimizer is suited for unbiased plan comparisons between 
various treatment approaches, based on large numbers of 
generated plans. Using Erasmus-iCycle, in Rotterdam, 
automated VMAT plan generation is now in full clinical use 
for prostate, head and neck, and cervical cancer. 
Material & Method:Erasmus-iCycle can be used for IMRT 
fluence optimization and individualized beam angle selection 
(iBAS). Given an input beam set containing all feasible beam 
directions, iBAS starts with an empty plan, i.e. zero beams 
(N=0), and at each step, it creates an N+1 beam plan, 
selecting the most optimal direction to be added to the N-
beam plan. Automated Erasmus-iCycle plan creation is 
steered by a list of planning requirements, a so-called 
wishlist, containing clinical constraints and objectives. The 
same wishlist is used for all patients of a certain treatment 
protocol (e.g. SBRT prostate cancer). Objectives are 
prioritized to give high priority to fulfilment of the most 
important clinical goals, compared to less important aims. 
Generally, PTV coverage has the highest priority. In 
comparisons of treatment strategies, the aim is to have equal 
PTV coverage for all strategies, allowing comparison of 
involved strategies based on doses delivered to the OAR. 
Results:An overview of the Erasmus-iCycle optimizer will be 
provided, with focus on automated beam angle selection. 
Results on plan comparisons for different beam geometries 
will be presented for prostate SBRT. In particular, non-
coplanar Cyberknife treatment with an MLC or circular cones, 
will be compared to treatments at a linac, including VMAT. 
